Domperidone and Risk of Serious Cardiac Events in Postpartum Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

184929 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-01

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the use of domperidone is associated with an increased risk of serious cardiac events among postpartum women in the six months following delivery. The hypothesis is that the use of domperidone will be associated with an increased risk of serious cardiac events among postpartum women.

The investigators will carry out separate population-based cohort studies using health care databases in five Canadian provinces. Women with live births will be eligible to enter the cohort. We will identify all women who start domperidone during the six months following delivery and match them to similar women who do not start domperidone, with all included women followed until the occurrence of an adverse cardiac event or for up to six months after delivery. The results from the separate sites will be combined to provide an overall assessment of the risk of serious cardiac events in users of domperidone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Domperidone and Risk of Sudden Cardiac Death

NCT02500108

Parkinson's Disease

COMPLETED

An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide

NCT01907633

Death, Sudden, Cardiac

COMPLETED

A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers

NCT01643889

Healthy

COMPLETED PHASE1

Bromocriptine in the Treatment of Peripartum Cardiomyopathy

NCT02590601

Peripartum Cardiomyopathy

WITHDRAWN PHASE3

Effect of Phenylephrine Versus Norepinephrine on Venous Return

NCT03872570

Arterial Hypotension

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall objective of this study is to determine whether the use of domperidone is associated with an increased risk of serious cardiac events among postpartum women in the six months following delivery. More specifically, the investigators will assess whether domperidone is associated with the risk of ventricular tachyarrhythmia (VT) and sudden cardiac death (SCD).

A distributed, common-protocol approach will be used to conduct retrospective cohort studies using administrative health care data from five Canadian provinces (Alberta, British Columbia, Manitoba, Ontario and Saskatchewan). Briefly, the Canadian databases include population-level data on physician billing, diagnoses and procedures from hospital discharge abstracts, and dispensations for prescription drugs. The Ontario data will be restricted to social assistance recipients.

To assess this potential drug safety issue, the investigators will use a prevalent new-user cohort design as described by Suissa et al., 2017. In each jurisdiction, the investigators will first assemble a base cohort that includes all women aged between 15 and 55 years old with live births between April 1, 1997 and December 31, 2016 (or the latest available data at each site). Base cohort entry will be defined by the hospital discharge date after delivery. From this base cohort, a study cohort will be formed including all women who received a prescription for domperidone during the six months following delivery and matched women who have a physician visit at the same follow-up time and do not receive domperidone. Study cohort entry will be defined by the prescription date of domperidone for exposed women or the corresponding date of the physician visit for unexposed women. Women will be followed from the study cohort entry date until an event (defined below) or end of follow up (six months after delivery). Women will be permitted to contribute more than one observation to the study provided that each observation meets all the inclusion criteria.

Exposure to domperidone will be defined as a prescription for domperidone during the six months following delivery. Women not exposed to domperidone will serve as the reference group. Analyses will be conducted using an approach analogous to an intention-to-treat. Unexposed women who are subsequently exposed to domperidone will be censored at the time of the domperidone prescription. The primary outcome will be a composite endpoint of VT or SCD. Secondary outcomes will be the individual endpoints of VT, SCD, and all-cause mortality; separate follow-up durations will be estimated for each outcome.

Using a prevalent new-user design with time-based exposure sets, each user of domperidone will be matched to 10 unexposed women with a physician visit within ±30 days of the first domperidone dispensing of the exposed woman. Matching will be done on propensity score and calendar date of base cohort entry (i.e., hospital discharge from delivery hospitalization). Cox proportional hazards models will be used to estimate site-specific adjusted hazards ratios (HR) and corresponding 95% confidential intervals (CI) for each outcome of interest among postpartum women. Robust sandwich variance estimators will be used to account for potential within-subject clustering. As secondary analyses, the composite endpoint of VT or SCD will be stratified by domperidone dose and duration if feasible. Sensitivity analyses will be performed to assess the robustness of study results. Meta-analyses of the site-specific results will be performed using random-effects models.

In additional analyses, the demographic and clinical characteristics (including perinatal and peripartum characteristics) of women prescribed domperidone in the six months postpartum with those of women not prescribed it during this period will be compared. Furthermore, the impact of Health Canada safety advisories on prescribing patterns will be assessed via interrupted time series analyses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventricular Tachyarrhythmia Sudden Cardiac Death Lactation Breast Feeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treated with domperidone

Women who received a prescription for domperidone during the six months following delivery.

Domperidone

Intervention Type DRUG

Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.

Unexposed group (reference)

Women with no prescription for domperidone during the six months following delivery.

No domperidone

Intervention Type DRUG

Women with no prescription for domperidone during the six months following delivery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Domperidone

Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.

Intervention Type DRUG

No domperidone

Women with no prescription for domperidone during the six months following delivery.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ATC A03FA03

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged between 15 and 55 years old with live births between April 1, 1997 and December 31, 2016 (or the latest available data at each site)

Exclusion Criteria

* Women with less than 365 days of healthcare coverage prior to the start of pregnancy
* Women with a domperidone prescription in the year prior to or during pregnancy
* Women with a diagnosis of Parkinson's disease or other diseases that cause autonomic dysfunction or use of antiparkinsonian agents anytime before delivery
* Women with a diagnosis of gastroparesis in the year prior to or during pregnancy
* Women with a diagnosis of ventricular tachyarrhythmia in the year prior to or during pregnancy

Minimum Eligible Age

15 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No